Search PubMed⌕ Search

Biomedical subjects

B Simon

Publications and source records attributed to B Simon.

At least 253 records · Page 14Linked to original sources
PubMed1985

[Healing rates following omeprazole and ranitidine treatment of gastric ulcer. Results of a German multicenter study].

The effectiveness of omeprazole (20 mg orally each morning) or ranitidine (150 mg orally twice daily) in the treatment of gastric ulcer was compared in 184 out-patient in a randomized, endoscopically controlled multi-centre double-blind ("double dummy") trial. Healing rates with omeprazole after two, four and eight weeks were 43, 81 and 95%, respectively, those with ranitidine were 45, 80 and 90%, a statistically not significant difference. Independently of medication, small ulcers (less than 8 mm diameter) healed more quickly than larger ones. Ulcers in the body of the stomach responded poorest to both drugs. Smoking had no statistically significant effect on healing rate. Omeprazole and ranitidine had similarly favourable effects on symptoms. Neither side effects nor changes in biochemical parameters could be ascribed to omeprazole. Both drugs had equivalent effects on the healing of gastric ulcers in the stated dosages.

Adult↗
PubMed1985

[Accelerated healing of ulcus ventriculi by a single evening dose of famotidine. Results of an Austrian-German-Italian multicenter study].

An 8 week, double-blind randomized, placebo-controlled multicenter trial was conducted in Austria, Germany and Italy to determine whether famotidine would speed healing and relief of symptoms in patients with benign gastric ulcer. Of the 131 patients who completed the trial, 66 received 40 mg famotidine in the evening and 65 placebo. At 4, 6, and 8 weeks after entry, ulcers had healed in a higher percentage of patients treated with famotidine than of those treated with placebo (47%, 70%, 91% vs 32%, 49%, 61%). In the famotidine group healing had occurred significantly more often after 6 and 8 weeks (p less than 0.05 and p less than 0.01 respectively). Famotidine was superior to placebo in relieving ulcer symptoms. The proportion of patients receiving additional antacid therapy was significantly lower in the famotidine group. The findings suggest that the new H2-receptor antagonist famotidine significantly speeds the healing of benign gastric ulcers in a single evening dose.

Adolescent↗
PubMed1985

[Short-term therapy of duodenal ulcer with omeprazole and ranitidine. Results of a German multicenter study].

In a randomized, endoscopically controlled double-blind trial the effectiveness of a single oral, morning dose of 40 mg omeprazole was compared with a twice daily oral dose of 150 mg ranitidine given to 334 ambulatory patients with duodenal ulcers. Under omeprazole 105 of 146 duodenal ulcers were demonstrated to have healed within 14 days (72%), compared with 95 of 160 (59%) on ranitidine. The difference is statistically significant (P = 0.0121). After 14 days smaller ulcers healed more quickly than large ones, regardless of the drug used: 80 of 110 with diameter 3-5 mm (73%); 48 of 90 with diameter more than 8 mm (53%). Smoking delayed healing [healing rate among non-smokers, 87 of 117 (74%); among smokers, 113 of 189 (60%)]. Healing rates among smokers receiving omeprazole and non-smokers receiving ranitidine were nearly identical. After 4 weeks, at 96 and 92% respectively, there was no difference in regard to healing rate. Both drugs had a similar influence on the symptoms. Thus, for the first time it has been demonstrated that omeprazole is superior to ranitidine after 14-day treatment of duodenal ulcer.

Adolescent↗
PubMed1985

Different effects of dietary chenodeoxycholic acid and ursodeoxycholic acid on colonic adenylate cyclase in the rat.

The oral administration of dietary chenodeoxycholic acid (1%), but not of ursodeoxycholic acid (1%), to male Sprague Dawley rats results in a significant increase in the colonic adenylate cyclase activity without any influence on the colonic cyclic-AMP phosphodiesterase activity. No effect of chronic bile acid feeding on the response of colonic adenylate cyclase to prostaglandin E2 and vasoactive intestinal peptide is observed. These data emphasize a dependence of the cyclic-AMP adenylate cyclase activation on the chemical structure of the bile acid. This may be of pathophysiologic relevance with respect to the frequently observed diarrhea as a side effect of oral chenodeoxycholic, but not ursodeoxycholic acid therapy for cholesterol gallstone dissolution in man.

3',5'-Cyclic-AMP Phosphodiesterases↗
PubMed1985

Famotidine versus ranitidine for the short-term treatment of duodenal ulcer.

One-hundred and eight-three patients with endoscopically proven duodenal ulcers, enrolled in this prospective, double-blind study, were randomly allocated to receive famotidine 40 mg once at night, 20 mg twice daily, 40 mg twice daily, or ranitidine 150 mg twice daily for 2-8 weeks. Pretreatment characteristics between the four groups were similar. After 4 weeks of treatment, among the famotidine-treated patients, 38 of 42 (90.5%) healed with the 40 mg once nightly regimen, 35 of 42 (83.3%) with 20 mg twice daily, and 37 of 41 (90.2%) with 40 mg twice daily. In the ranitidine group 40 of 43 patients (93.0%) healed. After 8 weeks of treatment, the respective data were: 97.6, 95.2, 100 and 93.0%. Different results between the famotidine groups and the ranitidine group were not statistically significant. All treatments were well tolerated and severe adverse events were rare. Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with ranitidine, indicating the importance of overnight gastric acidity in the pathogenesis of duodenal ulcer disease.

Adolescent↗
PubMed1985

Famotidine: nocturnal administration for gastric ulcer healing. Results of multicenter trials in Austria and Germany.

We conducted an 8-week, double-blind, randomized, placebo-controlled multicenter trial (Austria and Germany) to determine whether famotidine would speed healing or relief of symptoms in patients with benign gastric ulcer. Of the 65 patients who completed the trial, 32 received famotidine 40 mg once at night, and 33 received placebo. At 4, 6, and 8 weeks after entry, ulcers had healed in a larger percentage of patients treated with famotidine than in those treated with placebo (German multicenter trial: 65 vs. 46%, 95 vs. 71%, and 95 vs. 79%; Austrian multicenter trial: 42 vs. 44%, 67 vs. 44%, and 92 vs. 44%). In the famotidine group, healing had occurred significantly more often after 6 weeks (p less than 0.05). Famotidine was not superior to placebo in relieving ulcer symptoms. The findings suggest that famotidine in a single evening dose significantly hastens the healing of benign gastric ulcers.

Adolescent↗
PubMed1985

Patient-therapist sexual contact. I. Psychodynamic perspectives on the causes and results.

The problem of patient-therapist sexual contact is a substantial one, perhaps involving 5-10% of male therapists, and we suggest that the structure of psychotherapy and abundance of rescue fantasies make it inevitable. While skeptical of claims that there are any positive effects, we catalogue many negative effects: ambivalence and mistrust of subsequent therapists; patients doubting their own sense of reality; childhood trauma repeated and fixated instead of being interpreted; bondage to the offending therapist; original complaints of sexual dysfunction and problems in intimacy with men are exacerbated; burdens of guilt and shame carried by the patient; fantasy aspects of sexuality difficult to discuss in subsequent therapy, and the abrupt ending of the relationship leaving patient stranded and/or disorganized.

Adult↗
PubMed1985

Patient-therapist sexual contact. II. Problems of subsequent psychotherapy.

We use the catalogue of negative effects of sexual contact with the therapist (part I) to discuss the problems of subsequent therapy. Patient issues center around problems of trust, and anxiety and guilt around eventually exploring characterological issues involved in the sexual contact. From the therapist side (either as consultant or long-term therapist) problems include that of finding the best way of evaluating and understanding the patient's story (including its credibility); how to avoid repeating, in some new and disguised form, the previous therapist's counter-transference problems, and finally, the questions of if, when, and how is it therapeutic for the patient to report and press charges against the previous therapist. We recommend an ongoing role for the initial consultant in instances where such charges are to be pressed.

Adaptation, Psychological↗
PubMed1985

[Famotidine versus ranitidine in the acute treatment of duodenal ulcer. A multicenter comparative study in Germany].

185 patients with endoscopically proven duodenal ulcers were randomly allocated to treatment with either famotidine 40 mg nocte, 20 mg bid, 40 mg bid or ranitidine 150 mg bid for 2-8 weeks in a prospective double-blind study. The four groups were similar with regard to age, sex, duration of ulcer disease, smoking habits etc. After 2 weeks treatment 28/42 patients (66.7%) healed on famotidine 40 mg nocte, 24/42 patients (57.1%) on famotidine 20 mg bid, 26/41 patients (63.4%) on famotidine 40 mg bid and 28/43 patients (65,1%) on ranitidine 150 mg bid. The corresponding healing rates after 4 weeks were 90.5%, 83.3%, 90.2% and 93%, respectively. After 8 weeks more than 93% of the patients had healed ulcers. At each time there was no statistical difference between the different famotidine regimens and the ranitidine group. All treatments were well tolerated and severe adverse events were rare. Famotidine 40 mg at night, therefore, appears to be as good as conventional ranitidine.

Adolescent↗
PubMed1985

[Single evening administration of etintidine in the human: effect on acid secretion and behavior of important hormones].

The potency and duration of action of a single dose of etintidine, ranitidine and cimetidine were compared in placebo-controlled studies. In addition, the effect of a single night-time dose of etintidine (600 mg) on gastric acid secretion and basal hormone levels was assessed before, during and after a 28-day treatment. Nocturnal gastric acidity (23.00-07.00) was inhibited from 41.04 +/- 5.0 mmol/l to 12.9 +/- 2.8 mmol/l by 300 mg etintidine, to 6.50 +/- 2.5 mmol/l by 600 mg etintidine and to 8.58 +/- 2.5 mmol/l by 800 mg cimetidine nocte. Etintidine and cimetidine did not reduce H+-concentrations during the following day. Pentagastrin-stimulated acid output was virtually not affected after 600 mg etintidine and 800 mg cimetidine as well. By contrast, stimulated acid secretion was still suppressed by about 50% following 300 mg ranitidine. Basal levels of testosterone, prolactin etc. remained unchanged by 28-day etintidine (600 mg dose at night) treatment. Clinical studies are needed to examine the place of the single dose of etintidine (600 mg) at night for the short-term treatment of duodenal ulcer.

Adult↗
PubMed1985

[I.v. famotidine versus i.v. ranitidine: intragastric pH behavior in surgical intensive care patients].

20 patients of a surgical intensive care unit were treated in a randomised double-blind fashion with i.v. famotidine 10 mg and i.v. ranitidine every 6-12 hours for maximally seven days. Both groups were comparable with respect to the grade of risk of stress-induced bleeding. With both H2-blockers (ranitidine and famotidine) the intragastric pH could be increased to 5.0 and more and kept constant at this level over the whole test period. The mean daily doses required were 22.3 mg for famotidine and 154.3 mg for ranitidine. Stress-induced bleeding as well as adverse reactions could not be observed in both treatment groups.

Adolescent↗
PubMed1985

Intragastric acidity under 28-day omeprazole treatment.

The aim of our study was to investigate both the effect of 28-day treatment with omeprazole (30 mg orally once daily) and of repeated investigations on 24 h intragastric H+ activity. In double-blind randomized order, 10 healthy subjects received omeprazole and 5 placebo. 24 h acidity was determined before, during and after, treatment on days -8, -4, -1, 14 and 28, 32, 36, 42 and 70. A 90% reduction in the 24 h acid concentration was found after 14 and 28 days of treatment. Nocturnal H+ activity was decreased by 85%. No hyperacidity was observed after withdrawal of the drug. Control levels before, (between days -8 and -1) and after, therapy (between days 36 and 70), however, showed a significant increase in 24 h intragastric H+-activity. Summarizing, omeprazole 30 mg mane inhibits gastric acidity markedly both day and night. Repeated investigations at short intervals lead to a significant increase in intragastric acid concentration.

Adult↗
PubMed1985

Omeprazole heals duodenal, but not gastric ulcers more rapidly than ranitidine. Results of two German multicentre trials.

In two double-blind, randomized German multicentre trials the effects of omeprazole 20 mg mane and ranitidine 150 mg b.i.d. were compared for the first time in 334 outpatients with duodenal ulcer and 184 outpatients with gastric ulcer. In patients with duodenal ulcer endoscopically controlled healing rates after two weeks were 72% with omeprazole and 59% with ranitidine (p = 0.012); after 4 weeks 96 and 92%, resp. were healed (n.s.). In patients with gastric ulcer the healing rates after two, four, and eight weeks were 43, 81, and 95%, respectively, with omeprazole and 45, 80, and 90%, respectively, with ranitidine (n.s.). Smoking impaired healing in duodenal, but not in gastric ulcer. Symptom relief was comparable with both drugs. Serious side effects or clinically relevant changes in laboratory screening results were not detected. - Our results demonstrate for the first time that omeprazole 20 mg mane is superior to ranitidine 150 mg b.i.d. in the short-term treatment of duodenal, but not gastric ulcer.

Adolescent↗